Tarsus Pharmaceuticals (NASDAQ:TARS) Director William Phd Link Sells 27,116 Shares

Key Points

• William Phd Link, a director at Tarsus Pharmaceuticals, sold 27,116 shares for a total of $1,545,612, reducing his ownership by 15.91%.
• Tarsus recently reported an earnings miss, with a loss of $0.48 per share, falling short of analyst expectations by $0.15, despite revenue exceeding estimates at $102.66 million.
• The stock has seen trading volatility, recently falling 3.8% to $54.33, with a market capitalization of $2.29 billion.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) Director William Phd Link sold 27,116 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the transaction, the director owned 143,332 shares in the company, valued at approximately $8,169,924. The trade was a 15.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Tarsus Pharmaceuticals Trading Down 3.8%

TARS traded down $2.16 during midday trading on Wednesday, reaching $54.33. 542,695 shares of the company were exchanged, compared to its average volume of 659,072. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. Tarsus Pharmaceuticals, Inc. has a one year low of $30.23 and a one year high of $59.76. The stock has a market capitalization of $2.29 billion, a P/E ratio of -23.32 and a beta of 0.81. The stock's 50-day simple moving average is $47.97 and its 200 day simple moving average is $46.37.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.The company had revenue of $102.66 million for the quarter, compared to the consensus estimate of $95.81 million. As a group, analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds have recently modified their holdings of TARS. Paradigm Biocapital Advisors LP raised its position in Tarsus Pharmaceuticals by 3.1% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 2,610,197 shares of the company's stock valued at $134,086,000 after buying an additional 78,301 shares during the last quarter. Vanguard Group Inc. raised its position in Tarsus Pharmaceuticals by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company's stock valued at $114,380,000 after buying an additional 111,433 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at approximately $105,714,000. Lord Abbett & CO. LLC raised its position in Tarsus Pharmaceuticals by 4.0% in the 1st quarter. Lord Abbett & CO. LLC now owns 1,331,701 shares of the company's stock valued at $68,409,000 after buying an additional 51,714 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Tarsus Pharmaceuticals by 8.0% in the 2nd quarter. Geode Capital Management LLC now owns 934,420 shares of the company's stock valued at $37,859,000 after buying an additional 68,986 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a report on Monday, June 2nd. They set an "outperform" rating and a $75.00 target price on the stock. HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price on the stock in a report on Tuesday, May 27th. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Zacks Research upgraded Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, September 5th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.